Showing results (241-250 of 376) with videos related to

Sort By:
Pageof 38
The Journal of Antimicrobial Chemotherapy|April 12, 2022
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 studyMaria Saumoy, Jose Luís Sánchez-Quesada, Lambert Assoumou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2016
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV InfectionÁlvaro H Borges, Jacqueline Neuhaus, Abdel G Babiker, et al.
Open Forum Infectious Diseases|November 29, 2023
A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral ClassesJosé R Santos, Pere Domingo, Joaquín Portilla, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
Lipodystrophy and insulin resistance in combination antiretroviral treated HIV-1-infected patients: implication of resistinXavier Escoté, Merce Miranda, Sergi Veloso, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 10, 2007
[Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients]Josep Maria Llibre-Codina, Miguel Angel Casado-Gómez, Rainel Sánchez-de la Rosa, et al.
AIDS Research and Human Retroviruses|April 21, 2006
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patientsAnna Bonjoch, Roger Paredes, Pere Domingo, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched studyDaniel K Nomah, Juliana Reyes-Urueña, Yesika Díaz, et al.
HIV Clinical Trials|March 18, 2015
Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP studyEnric Pedrol, Ana M Caro-Murillo, Manuel A Castaño, et al.
Eclinicalmedicine|August 12, 2022
Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort studyRaquel Martin-Iguacel, Juliana Reyes-Urueña, Andreu Bruguera, et al.
Antiviral Therapy|December 3, 2003
Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitorsEsteban Martínez, Pere Domingo, Esteban Ribera, et al.
Pageof 38